$PNW

Morgan Stanley Adjusts Price Target on Pinnacle West Capital to $91 From $89

Morgan Stanley raised its price target for Pinnacle West Capital to $91 from $89. The stock has seen a 16.01% increase year-to-date and a 1.30% rise over the past year. Jefferies also recently adjusted its target to $109 from $129, maintaining a buy rating.

Original reporting
Published Oct 21, 2026, 9:44 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 10:22 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$PNW
Bullish
medium confidence
Mentioned
$PNW
Relevance
5/10
AlphAI data visualization · based on marketscreener.com
Decision brief

The 30-second read

$PNWBullishMed
01

Why it matters

A small upward revision signals modest confidence but is unlikely to trigger a large price move.

02

Market read

The article offers a minor analyst upgrade for PNW, providing limited trading impetus.

03

What to watch

Potential exposure to regulatory changes or weather‑related demand shifts not addressed in the target update.

Relevance 5/10Novelty 5/10Timing: pre-market today

Background

Pinnacle West Capital (PNW) is a utility company serving the Phoenix area. Analyst price‑target adjustments are routine but can influence short‑term trading.

Company-level read

Ticker impact

$PNWBullishMedium confidence
Context

Morgan Stanley raised its price target for Pinnacle West Capital to $91 from $89, indicating a modest upgrade.

Expected impact

likely modest upward pressure as investors price in the higher target.

Evidence & confidence

Analyst target changes often move the stock modestly, especially when the adjustment is small.

Market effects

Minimal impact on the utility sector; the change reflects company‑specific outlook rather than sector trends.

Limited to U.S. utility investors; no broader regional effect.

Low; the news is confined to a single U.S. utility stock.

Counterpoint

The modest target raise may be insufficient to offset broader market risks for utilities.

Key entities

  • Morgan Stanley

    Provided the new price target for PNW.

  • Pinnacle West Capital

    Utility company whose price target was adjusted.

Related articles

$PNWMedAI 8/10

Pinnacle West Capital (PNW) Q2 2026 Earnings Call Transcript

Pinnacle West Capital (PNW) reported Q2 2026 net income of $178.6M versus $192.6M in Q2 2025, with diluted EPS of $1.43 versus $1.58. Operating revenues rose to $1.46B from $1.36B. Management cited 9.6% weather-normalized sales growth, 9,164 MW peak demand, and a $265B Arizona TSMC investment plan. Full-year EPS guidance is $4.55 to $4.75.

$PNWMed

PINNACLE WEST REPORTS LOWER 2026 SECOND-QUARTER FINANCIAL RESULTS COMPARED TO A YEAR AGO

PINNACLE WEST CAPITAL CORP (PNW) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FOR IMMEDIATE RELEASE August 4, 2026 Media Contact: Analyst Contact: Alan Bunnell (602) 250-3376 Amanda Ho (602) 250-3334 Website: pinnaclewest.com PINNACLE WEST REPORTS LOWER 2026 SECOND-QUARTER FINANCIAL RESULTS COMPARED TO A YEAR AGO • Lower second-quarter financi

$MRNAHigh

Moderna's melanoma vaccine succeeds in major trial. So why did its stock plunge?

Moderna and Merck's experimental melanoma vaccine, combined with Keytruda, reduced recurrence or death risk by 42% in a Phase 3 trial. Despite positive results, Moderna's shares fell 18%, likely due to high investor expectations. The vaccine is personalized using mRNA technology, targeting unique tumor mutations. Trial data showed 82.2% of patients treated with the vaccine and Keytruda were alive without recurrence after two years, compared to 70% with Keytruda alone.

$VRTXMed

Vertex Highlights Kidney Pipeline as Povetacicept Cuts Proteinuria 52% in Phase III

Vertex Pharmaceuticals reported positive Phase III results for povetacicept, showing a 52% reduction in proteinuria in kidney disease patients. The drug's safety profile was similar to placebo. Vertex also discussed inaxaplin's potential in treating APOL1-mediated kidney disease, with Phase III AMPLITUDE trial results expected early next year. The company is engaging with payers for povetacicept's commercial coverage.